Analysis using the Oncomine platform revealed a significant increase in the transcription level of Nuf2 in a variety of cancerous tissues compared to normal tissues, including liver and other 14 types of cancers (bladder, brain and central nervous system, breast, cervical, colorectal, esophageal, gastric, head and neck, lung, lymphoma, melanoma, ovarian, pancreatic, and prostate cancers) (Figure 1A). This evidence concerns the gene NUF2 and prostate carcinoma.